<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ACEMETACIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ACEMETACIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain and inflammation in rheumatic disease</span>,
                <span class="indication">Pain and inflammation in other musculoskeletal disorders</span>,
                <span class="indication">Postoperative analgesia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                120 mg daily in divided doses, then increased if necessary to 180 mg daily in divided doses, dose to be taken with food.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Glycolic acid ester of indometacin.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk.</p><p>NSAIDs should be avoided during the third trimester because use is associated with a risk of closure of fetal ductus arteriosus <i>in utero</i> and possibly persistent pulmonary hypertension of the newborn. In addition, the onset of labour may be delayed and its duration may be increased.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p><p>Avoid in severe liver disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>The lowest effective dose should be used for the shortest possible duration.</p>
            </section>
        
            <section class="generalInformation">
              <p>Avoid if possible or use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active gastro-intestinal bleeding</li>
            <li>active gastro-intestinal ulceration</li>
            <li>history of gastro-intestinal bleeding related to previous NSAID therapy</li>
            <li>history of gastro-intestinal perforation related to previous NSAID therapy</li>
            <li>history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)</li>
            <li>history of recurrent gastro-intestinal ulceration (two or more distinct episodes)</li>
            <li>severe heart failure</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), blood disorders, confusion, convulsions, hepatic damage, hyperglycaemia, interstitial fibrosis associated with NSAIDs can lead to renal failure, intestinal strictures, pancreatitis, papillary necrosis associated with NSAIDs can lead to renal failure, peripheral neuropathy, psychiatric disturbances, pulmonary eosinophilia, Stevens-Johnson syndrome, syncope, thrombocytopenia, toxic epidermal necrolysis, visual disturbances,
              </p>
              <p>
                <strong>notKnown:</strong> Angioedema, blood disorders, bronchospasm, colitis (induction of or exacerbation of), Crohn&#8217;s disease (induction of or exacerbation of), depression, diarrhoea, dizziness, drowsiness, fluid retention (rarely precipitating congestive heart failure), gastro-intestinal bleeding, gastro-intestinal discomfort, gastro-intestinal disturbances, gastro-intestinal ulceration, haematuria, headache, hearing disturbances, hyperkalaemia, hypersensitivity reactions, insomnia, nausea, nervousness, photosensitivity, raised blood pressure, rashes, renal failure (especially in patients with pre-existing renal impairment), tinnitus, vertigo,
              </p>
        
        
            <section class="advice">
                <h3>Serious side-effects</h3>
              <p>For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see <xref format="dita" href="#PHP78612" type="bookmark" namespace="/treatment-summaries/non-steroidal-anti-inflammatory-drugs">Non-steroidal anti-inflammatory drugs</xref>.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>NSAIDs and cardiovascular events</h3>
              <p>All NSAID use (including cyclo-oxygenase-2 selective inhibitors) can, to varying degrees, be associated with a small increased risk of thrombotic events (e.g. myocardial infarction and stroke) independent of baseline cardiovascular risk factors or duration of NSAID use; however, the greatest risk may be in those receiving high doses long term.</p><p>
            <b>Cyclo-oxygenase-2 selective inhibitors</b>, <b>diclofenac</b> (150&#8239;mg daily) and<b> ibuprofen</b> (2.4&#8239;g daily) are associated with an increased risk of thrombotic events. The increased risk for diclofenac is similar to that of licensed doses of <b>etoricoxib</b>. <b>Naproxen</b> (1&#8239;g daily) is associated with a lower thrombotic risk, and low doses of ibuprofen (1.2&#8239;g daily or less) have not been associated with an increased risk of myocardial infarction.</p><p>The lowest effective dose of NSAID should be prescribed for the shortest period of time to control symptoms and the need for long-term treatment should be reviewed periodically.</p>
            </section>
            <section class="importantSafetyInformation">
                <h3>NSAIDs and gastro-intestinal events</h3>
              <p>All NSAIDs are associated with serious gastro-intestinal toxicity; the risk is higher in the elderly. Evidence on the relative safety of non-selective NSAIDs indicates differences in the risks of serious upper gastro-intestinal side-effects&#8212;piroxicam, ketoprofen, and ketorolac are associated with the highest risk; indometacin, diclofenac, and naproxen are associated with intermediate risk, and ibuprofen with the lowest risk (although high doses of ibuprofen have been associated with intermediate risk). <b>Selective inhibitors of cyclo-oxygenase-2</b> are associated with a <i>lower risk</i> of serious upper gastro-intestinal side-effects than non-selective NSAIDs.</p><p>Recommendations are that NSAIDs associated with a low risk e.g. ibuprofen are <i>generally preferred</i>, to start at the <i>lowest recommended dose</i> and not to use more than one oral NSAID at a time.</p><p>The combination of a NSAID and low-dose aspirin can increase the risk of gastro-intestinal side-effects; this combination should be used only if absolutely necessary and the patient should be monitored closely.</p>
            </section>
            <section class="importantSafetyInformation">
                <h3>Asthma</h3>
              <p>Any degree of worsening of asthma may be related to the ingestion of NSAIDs, either prescribed or (in the case of ibuprofen and others) purchased over the counter.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Allergic disorders
          </li>
          <li>
            cardiac impairment (NSAIDs may impair renal function)
          </li>
          <li>
            cerebrovascular disease
          </li>
          <li>
            coagulation defects
          </li>
          <li>
            connective-tissue disorders
          </li>
          <li>
            Crohn&#8217;s disease (may be exacerbated)
          </li>
          <li>
            elderly (risk of serious side-effects and fatalities)
          </li>
          <li>
            epilepsy
          </li>
          <li>
            heart failure
          </li>
          <li>
            ischaemic heart disease
          </li>
          <li>
            parkinsonism
          </li>
          <li>
            peripheral arterial disease
          </li>
          <li>
            psychiatric disturbances
          </li>
          <li>
            risk factors for cardiovascular events
          </li>
          <li>
            ulcerative colitis (may be exacerbated)
          </li>
          <li>
            uncontrolled hypertension
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Caution&#8212;long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>During prolonged therapy ophthalmic and blood examinations particularly advisable.</p>
            </section>
      </section>










      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID&#8212;which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ACEMETACIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77532"><a href="../medicinalForm/PHP77532.html" data-target="#PHP77532" data-action="load">Capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
